Loading...
•
Sep 30, 2020
Prothena Q3 2020 Earnings Report
Reported financial results for the third quarter of 2020 and provided an R&D update.
Key Takeaways
Prothena reported a net loss of $30.6 million for the third quarter of 2020. Roche presented data from the Phase 2 PASADENA study of prasinezumab in patients with early Parkinson’s disease and announced that prasinezumab will advance into a late-stage study.
Net cash used in operating and investing activities was $19.5 million with quarter-end cash and restricted cash position of $317.2 million.
Roche presented results from the Phase 2 PASADENA study of prasinezumab in patients with early Parkinson’s disease.
Roche and Prothena will advance prasinezumab into late-stage clinical development.
Presented new preclinical data from two Alzheimer’s disease programs at CTAD 2020
Prothena
Prothena
Prothena Revenue by Segment
Revenue by Segment
Collaboration Revenue
CapyFin.com Forward Guidance
The Company continues to expect its full year 2020 net cash burn from operating and investing activities to be $75-$85 million, and expects to end the year with approximately $299 million in cash, cash equivalents and restricted cash (midpoint).